enGene Therapeutics (ENGN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.67, -2.34% vs the prior close of $1.71.
- Volume 1.16M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ENGN dips 2.3% to $1.67. Closed at $1.67, -2.34% vs the prior close of $1.71. Day range $1.65–$1.75, opened at $1.73.
ENGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ENGN dips 2.3% to $1.67
- Closed at $1.67, -2.34% vs the prior close of $1.71. Day range $1.65–$1.75, opened at $1.73.
- Volume was 1.16M shares, 1.5x its 50-day average of 756.45K.
- Price is -8.9% vs its 50-day average ($1.83) and -64.6% vs its 200-day average ($4.72).
- 52-week range $1.40–$12.25; today's close sits at 2% of that range, 86.4% below the 52-week high.
Oct 15, 2026 — ENGN jumps 9.6% to $1.71
- Closed at $1.71, +9.62% vs the prior close of $1.56. Day range $1.58–$1.74, opened at $1.61.
- Volume was 1.18M shares, 1.6x its 50-day average of 736.04K.
- Price is -6.8% vs its 50-day average ($1.84) and -64.1% vs its 200-day average ($4.76).
- 52-week range $1.40–$12.25; today's close sits at 3% of that range, 86.0% below the 52-week high.
Oct 14, 2026 — ENGN slides 4.3% to $1.56, a 3-month low, 4 down days in a row
- Closed at $1.56, -4.29% vs the prior close of $1.63. Day range $1.56–$1.62, opened at $1.60.
- Volume was 943.50K shares, 1.3x its 50-day average of 729.99K.
- Price is -15.1% vs its 50-day average ($1.84) and -67.5% vs its 200-day average ($4.79).
- 52-week range $1.40–$12.25; today's close sits at 1% of that range, 87.3% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — ENGN slides 4.1% to $1.63, a 3-month low, 3 down days in a row
- Closed at $1.63, -4.12% vs the prior close of $1.70. Day range $1.62–$1.70, opened at $1.69.
- Volume was 913.80K shares, 1.3x its 50-day average of 722.22K.
- Price is -11.5% vs its 50-day average ($1.84) and -66.3% vs its 200-day average ($4.83).
- 52-week range $1.40–$12.25; today's close sits at 2% of that range, 86.7% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — ENGN dips 1.7% to $1.70, a 1-month low
- Closed at $1.70, -1.73% vs the prior close of $1.73. Day range $1.69–$1.74, opened at $1.73.
- Volume was 462.70K shares, 0.6x its 50-day average of 719.09K.
- Price is -7.8% vs its 50-day average ($1.84) and -65.1% vs its 200-day average ($4.87).
- 52-week range $1.40–$12.25; today's close sits at 3% of that range, 86.1% below the 52-week high.
Oct 9, 2026 — ENGN dips 2.8% to $1.73, a 1-month low
- Closed at $1.73, -2.81% vs the prior close of $1.78. Day range $1.72–$1.81, opened at $1.76.
- Volume was 359.10K shares, 0.5x its 50-day average of 726.53K — lighter than usual.
- Price is -6.3% vs its 50-day average ($1.85) and -64.8% vs its 200-day average ($4.91).
- 52-week range $1.40–$12.25; today's close sits at 3% of that range, 85.9% below the 52-week high.
Oct 8, 2026 — ENGN rises 2.0% to $1.78 on 2.1x normal volume
- Closed at $1.78, +2.01% vs the prior close of $1.75. Day range $1.68–$1.79, opened at $1.75.
- Volume was 1.46M shares, 2.1x its 50-day average of 708.50K — unusually heavy trading.
- Price is -3.6% vs its 50-day average ($1.85) and -64.0% vs its 200-day average ($4.95).
- 52-week range $1.40–$12.25; today's close sits at 4% of that range, 85.5% below the 52-week high.
Oct 7, 2026 — ENGN slides 3.1% to $1.75, a 1-month low, 5 down days in a row
- Closed at $1.75, -3.06% vs the prior close of $1.80. Day range $1.74–$1.86, opened at $1.80.
- Volume was 708.30K shares, 1.0x its 50-day average of 705.99K.
- Price is -5.5% vs its 50-day average ($1.85) and -65.0% vs its 200-day average ($4.98).
- 52-week range $1.40–$12.25; today's close sits at 3% of that range, 85.8% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — ENGN slides 3.7% to $1.80, 4 down days in a row
- Closed at $1.80, -3.74% vs the prior close of $1.87. Day range $1.80–$1.87, opened at $1.87.
- Volume was 361.70K shares, 0.5x its 50-day average of 711.71K — lighter than usual.
- Price is -2.6% vs its 50-day average ($1.85) and -64.1% vs its 200-day average ($5.01).
- 52-week range $1.40–$12.25; today's close sits at 4% of that range, 85.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — ENGN slides 3.6% to $1.87, 3 down days in a row
- Closed at $1.87, -3.61% vs the prior close of $1.94. Day range $1.78–$1.94, opened at $1.94.
- Volume was 952.90K shares, 1.3x its 50-day average of 705.97K.
- Price is +1.3% vs its 50-day average ($1.85) and -62.9% vs its 200-day average ($5.04).
- 52-week range $1.40–$12.25; today's close sits at 4% of that range, 84.7% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ENGN dips 2.0% to $1.94
- Closed at $1.94, -2.02% vs the prior close of $1.98. Day range $1.93–$2.02, opened at $2.00.
- Volume was 690.10K shares, 1.0x its 50-day average of 725.36K.
- Price is +5.1% vs its 50-day average ($1.85) and -61.8% vs its 200-day average ($5.08).
- 52-week range $1.40–$12.25; today's close sits at 5% of that range, 84.2% below the 52-week high.
ENGN latest news & SEC filings
Every SEC filing by or about ENGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Grossman William bought 5,102 shares at $1.97 (≈$10.05K) on Sep 22, 2026; now holds 5,102
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jul 31, 2026:
- Net income: -$32.50M (prior year -$28.99M) (loss widened vs Jul 31, 2025)
- Diluted EPS: -$0.47 (prior year -$0.57) (loss narrowed vs Jul 31, 2025)
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 22, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ENGN
- Last results release: Sep 8, 2026 (8-K Item 2.02). Previous ones: Jun 15, 2026, Mar 9, 2026, Dec 22, 2025. Based on that rhythm, the next report is likely around Dec 8, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.01% (largest 9.6%). That is a volatile stock.
- Liquidity: about 851.32K shares (≈$1.42M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.67 vs a range of $1.40–$12.25 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: William Grossman bought 5,102 shares on Sep 22, 2026.
- Latest filings: 10-Q Sep 8, 2026; 8-K Sep 8, 2026; 8-K Aug 11, 2026.
- Share count: 67.02M shares outstanding (Sep 2, 2026), +30.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ENGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.73 | 1.75 | 1.65 | 1.67 | 1.16M |
| Oct 15, 2026 | 1.61 | 1.74 | 1.58 | 1.71 | 1.18M |
| Oct 14, 2026 | 1.60 | 1.62 | 1.56 | 1.56 | 943.50K |
| Oct 13, 2026 | 1.69 | 1.70 | 1.62 | 1.63 | 913.80K |
| Oct 12, 2026 | 1.73 | 1.74 | 1.69 | 1.70 | 462.70K |
| Oct 9, 2026 | 1.76 | 1.81 | 1.72 | 1.73 | 359.10K |
| Oct 8, 2026 | 1.75 | 1.79 | 1.68 | 1.78 | 1.46M |
| Oct 7, 2026 | 1.80 | 1.86 | 1.74 | 1.75 | 708.30K |
| Oct 6, 2026 | 1.87 | 1.87 | 1.80 | 1.80 | 361.70K |
| Oct 5, 2026 | 1.94 | 1.94 | 1.78 | 1.87 | 952.90K |
| Oct 2, 2026 | 2.00 | 2.02 | 1.93 | 1.94 | 690.10K |
| Oct 1, 2026 | 2.01 | 2.01 | 1.96 | 1.98 | 903.00K |
| Sep 30, 2026 | 1.97 | 2.02 | 1.93 | 2.00 | 1.28M |
| Sep 29, 2026 | 1.97 | 1.97 | 1.91 | 1.95 | 393.20K |
| Sep 28, 2026 | 1.96 | 1.98 | 1.90 | 1.97 | 332.20K |
| Sep 25, 2026 | 1.94 | 1.97 | 1.88 | 1.96 | 1.98M |
| Sep 24, 2026 | 1.99 | 1.99 | 1.90 | 1.92 | 796.30K |
| Sep 23, 2026 | 2.05 | 2.05 | 1.98 | 2.00 | 669.00K |
| Sep 22, 2026 | 1.96 | 2.08 | 1.96 | 2.05 | 1.06M |
| Sep 21, 2026 | 1.92 | 1.97 | 1.90 | 1.96 | 426.30K |
About enGene Therapeutics
enGene Therapeutics (ENGN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAINT-LAURENT. State of incorporation: Canada (Federal Level). Fiscal year ends October 31. SEC CIK 1980845.
ENGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Philip Astley-Sparke | Director | Jun 17, 2026 |
| Gerald A Brunk | Director | Jun 17, 2026 |
| Ronald Harold Wilfred Cooper | CEO & President | Feb 3, 2026 |
| Richard M Glickman | Director | Jun 17, 2026 |
| William Grossman | Interim Chief Medical Officer | Sep 24, 2026 |
| Paul J Hastings | Director | Jun 17, 2026 |
| Michael Thomas Heffernan | Director | Jun 17, 2026 |
| Wouter Joustra | Director | Jun 17, 2026 |
| Lota S. Zoth | Director | Jun 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matthew Ross Boyd | Chief Regulatory Officer | Feb 3, 2026 |
| Jill Buck | Chief Development Officer | Feb 3, 2026 |
| Anthony Tzeyew Cheung | Chief Scientific Officer | Feb 3, 2026 |
| Constantine Chinoporos | Interim Chief Business Officer | Jul 22, 2026 |
| Joan Connolly | Chief Technology Officer | Feb 3, 2026 |
| Ronald Harold Wilfred Cooper | CEO & President | Feb 3, 2026 |
| D. Ryan Daws | Chief Financial Officer | Feb 3, 2026 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | Feb 3, 2026 |
| William Grossman | Interim Chief Medical Officer | Sep 24, 2026 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | Feb 3, 2026 |
| Kathleen P. Richton | SVP, Finance and Treasurer | Jul 22, 2026 |
| Hussein Sweiti | Chief Medical Officer | Oct 1, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
| Sep 22, 2026 | William Grossman | Buy | 5,102 | $1.97 |
ENGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Oct 31, 2025 | — | $-117.30M | 2.29 | $-99.24M |
| Oct 31, 2024 | — | $-55.14M | 1.46 | $-48.28M |
| Oct 31, 2023 | — | $-99.92M | 151.22 | $-24.74M |
| Oct 31, 2022 | — | $-24.46M | 44.30 | $-17.59M |
Latest balance sheet: total assets $288.32M, total liabilities $58.03M, cash $41.02M (as of Jul 31, 2026).
ENGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 8, 2026 | 8-K Item 2.02 (results) | $1.92 |
| Jun 15, 2026 | 8-K Item 2.02 (results) | $1.77 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $7.05 |
| Dec 22, 2025 | 8-K Item 2.02 (results) | $8.77 |
| Sep 11, 2025 | 8-K Item 2.02 (results) | $6.06 |
| Jun 12, 2025 | 8-K Item 2.02 (results) | $3.25 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $5.24 |
| Dec 19, 2024 | 8-K Item 2.02 (results) | $5.96 |
| Sep 10, 2024 | 8-K Item 2.02 (results) | — |
| Jun 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Jan 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ENGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.